OraSure Technologies, Inc. (OSUR)
| Market Cap | 934.68M |
| Revenue (ttm) | 158.53M |
| Net Income (ttm) | -14.34M |
| Shares Out | 71.54M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $12.92 |
| Previous Close | $12.86 |
| Change ($) | 0.06 |
| Change (%) | 0.47% |
| Day's Open | 12.90 |
| Day's Range | 12.72 - 13.25 |
| Day's Volume | 697,927 |
| 52-Week Range | 5.57 - 19.58 |
OraSure: Well Positioned Ex-Covid, Sell Side Missing The Organic Growth Drivers
BETHLEHEM, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. E...
BETHLEHEM, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laborato...
OTTAWA, Dec. 23, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and anal...
BETHLEHEM, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that th...
BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr...
BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in the fight against HIV, today announced its plans to commemorate World AIDS Day. On Tues...
BETHLEHEM, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laborato...
A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance. The post Stock Upgrades: Orasure Technologies Shows Rising Relative Strength appeared first o...
OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript
OraSure (OSUR) delivered earnings and revenue surprises of 114.29% and 11.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Net T hird Q uarter R evenues of $ 48.0 M illion Increased 33 % Year-Over-Year, D riven by $ 18 . 4 M illion in S ales of O ral F luid C ollection D evices for COVID-19 M olecular T esting
Second FDA EUA for the Subsidiary's Saliva Collection Devices Second FDA EUA for the Subsidiary's Saliva Collection Devices
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure receives emergency use authorization for OMNIgene. Keros Therapeutics initiates Phase 2 clinical trial for Myelodysplastic Syndromes.
BETHLEHEM, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 third quarter financial results and...
The FDA granted Emergency Use Authorization for the company's at-home saliva collection device for coronavirus testing.
OraSure Technologies (OSUR) is in the news Monday after announcing approval from the FDA for one of its devices sent OSUR stock soaring. The post OraSure Technologies News: Why OSUR Stock Is S...
Shares of OraSure Technologies, Inc. (NASDAQ: OSUR) were advancing strongly Monday after the diagnostic company said its DNA Genotek subsidiary's saliva collection device used in COVID-19 test...
OraSure Technologies Inc. (NASDAQ: OSUR) shares jumped to start off the week after the company announced an update from the U.S.
BETHLEHEM, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory ...
Investors need to pay close attention to OraSure (OSUR) stock based on the movements in the options market lately.
BETHLEHEM, Pa., Sept. 24, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laborato...
A prominent Harvard epidemiologist and expert in disease testing thinks a cheap, daily, do-it-yourself test can be as effective as a vaccine at cutting coronavirus transmission, according to a...
BETHLEHEM, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laborato...
BETHLEHEM, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome labora...
A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance. The post Stocks With Rising Relative Price Strength: Orasure Technologies appeared first on ...
OraSure Technologies, Inc. (OSUR) CEO Steve Tang on Q2 2020 Results - Earnings Call Transcript
OraSure (OSUR) delivered earnings and revenue surprises of -77.78% and -14.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BETHLEHEM, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laborator...
BETHLEHEM, Pa., July 31, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laborator...
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2020 Second Quarter Earnings Conference Call Wednesday, August 5, 2020, 5:00 p.m. ET
MORRISVILLE, N.C., June 17, 2020 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborat...
OTTAWA, June 17, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and an...
BETHLEHEM, Pa., June 10, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory...
The number of EUAs utilizing OraSure’s saliva collection products continues to grow The number of EUAs utilizing OraSure’s saliva collection products continues to grow
BETHLEHEM, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the full exercise by the underwriters of their option...
BETHLEHEM, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the pricing of an underwritten offering of 8,000,000 ...
BETHLEHEM, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced it has commenced an underwritten public offering of 8...
Acquisition strengthens OraSure’s leadership position in HIV field Acquisition strengthens OraSure’s leadership position in HIV field
BETHLEHEM, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory...
OTTAWA, May 22, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and ana...
ST. PAUL, Minn. and OAKLAND, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ: OSUR), and Nom Nom™, a direct-to-consumer pet healt...
All Microbiome Services to be Unified under the Diversigen Brand
OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q1 2020 Results - Earnings Call Transcript
Board Change Also Announced Board Change Also Announced
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Other Board Changes Also Announced Other Board Changes Also Announced
BETHLEHEM, Pa., April 06, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laborator...
About OSUR
OraSure Technologies, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antig... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Nov 12, 1986 |
| CEO Douglas Michels | Employees 472 |
| Stock Exchange NASDAQ | Ticker Symbol OSUR |
Financial Performance
In 2019, OSUR's revenue was $154.61 million, a decrease of -14.93% compared to the previous year's $181.74 million. Earnings were $16.66 million, a decrease of -18.34%.
Analyst Forecasts
According to 7 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is 18.86, which is an increase of 45.98% from the latest price.